Skip to main content
Top
Gepubliceerd in: Quality of Life Research 7/2018

21-04-2018

Quality of life of patients with gastrointestinal cancers undergoing chemotherapy

Auteurs: Ilufredo Y. Tantoy, Bruce A. Cooper, Anand Dhruva, Janine Cataldo, Steven M. Paul, Yvette P. Conley, Marilyn Hammer, Kord M. Kober, Jon D. Levine, Christine Miaskowski

Gepubliceerd in: Quality of Life Research | Uitgave 7/2018

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail

Abstract

Purpose

Findings regarding changes in the quality of life (QOL) of patients with gastrointestinal cancers (GI) undergoing chemotherapy (CTX) are inconclusive. Purpose was to evaluate for changes in QOL scores of patients with GI cancers over two cycles of CTX.

Methods

Patients (n = 397) completed disease-specific [i.e., Quality of Life-Scale-Patient Version (QOL-PV)] and generic [12-item Medical Outcomes Study Short Form Survey (SF-12)] measures of QOL a total of six times over two cycles of CTX. Changes in these QOL scores were evaluated using bootstrapped multilevel regression with full information maximum likelihood estimation. Treatment group (i.e., with or without targeted therapy), age, number of metastatic sites, time from cancer diagnosis, number of prior cancer treatments, GI cancer diagnosis (i.e., colon/rectum/anal vs. other), and CTX regimen were evaluated as covariates in the conditional models for each of the QOL scores.

Results

During the second cycle of CTX, QOL-PV scores decreased in the week following CTX administration, and then increased the following week. For both cycles of CTX, the physical component summary and mental component summary scores of the SF-12 decreased in the week following CTX administration and then increased the following week. Increased time from cancer diagnosis and a higher number of prior cancer treatments resulted in worse QOL-PV and SF-12 scores at enrollment.

Conclusions

While changes in QOL scores over the two CTX cycles were statistically significant, the differences were not clinically meaningful. Future studies need to determine the optimal timing of QOL assessments to assess changes associated with cancer treatments.
Literatuur
1.
2.
go back to reference McCahill, L. E., Yothers, G., Sharif, S., Petrelli, N. J., Lai, L. L., Bechar, N., et al. (2012). Primary mFOLFOX6 plus bevacizumab without resection of the primary tumor for patients presenting with surgically unresectable metastatic colon cancer and an intact asymptomatic colon cancer: Definitive analysis of NSABP trial C-10. Journal of Clinical Oncology, 30(26), 3223–3228.CrossRefPubMedPubMedCentral McCahill, L. E., Yothers, G., Sharif, S., Petrelli, N. J., Lai, L. L., Bechar, N., et al. (2012). Primary mFOLFOX6 plus bevacizumab without resection of the primary tumor for patients presenting with surgically unresectable metastatic colon cancer and an intact asymptomatic colon cancer: Definitive analysis of NSABP trial C-10. Journal of Clinical Oncology, 30(26), 3223–3228.CrossRefPubMedPubMedCentral
3.
go back to reference Howell, D., Molloy, S., Wilkinson, K., Green, E., Orchard, K., Wang, K., et al. (2015). Patient-reported outcomes in routine cancer clinical practice: A scoping review of use, impact on health outcomes, and implementation factors. Annals of Oncology, 26(9), 1846–1858.CrossRefPubMed Howell, D., Molloy, S., Wilkinson, K., Green, E., Orchard, K., Wang, K., et al. (2015). Patient-reported outcomes in routine cancer clinical practice: A scoping review of use, impact on health outcomes, and implementation factors. Annals of Oncology, 26(9), 1846–1858.CrossRefPubMed
4.
go back to reference Post, M. W. (2014). Definitions of quality of life: What has happened and how to move on. Topics in Spinal Cord Injury and Rehabilitation, 20(3), 167–180.CrossRef Post, M. W. (2014). Definitions of quality of life: What has happened and how to move on. Topics in Spinal Cord Injury and Rehabilitation, 20(3), 167–180.CrossRef
5.
go back to reference Khanna, D., & Tsevat, J. (2007). Health related quality of life: An introduction. American Journal of Managed Care, 13(9), S218–S223.PubMed Khanna, D., & Tsevat, J. (2007). Health related quality of life: An introduction. American Journal of Managed Care, 13(9), S218–S223.PubMed
6.
go back to reference Ware, J. E. Jr., & Sherbourne, C. D. (1992). The MOS 36-item short-form health survey (SF-36): I. Conceptual framework and item selection. Medical Care, 30(6), 473–483.CrossRefPubMed Ware, J. E. Jr., & Sherbourne, C. D. (1992). The MOS 36-item short-form health survey (SF-36): I. Conceptual framework and item selection. Medical Care, 30(6), 473–483.CrossRefPubMed
7.
go back to reference Group, T. E. (1990). EuroQol—a new facility for the measurement of health-related quality of life. Health Policy, 16(3), 199–208.CrossRef Group, T. E. (1990). EuroQol—a new facility for the measurement of health-related quality of life. Health Policy, 16(3), 199–208.CrossRef
8.
go back to reference Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., et al. (1993). The European Organization for Research and Treatment Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. Journal of the National Cancer Institute, 85(5), 365–376.CrossRefPubMed Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., et al. (1993). The European Organization for Research and Treatment Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. Journal of the National Cancer Institute, 85(5), 365–376.CrossRefPubMed
9.
go back to reference Cella, D. F., Tulsky, D. S., Gray, G., Sarafian, B., Linn, E., Bonomi, A., et al. (1993). The functional assessment of cancer therapy scale: Development and validation of the general measure. Journal of Clinical Oncology, 11(3), 570–579.CrossRefPubMed Cella, D. F., Tulsky, D. S., Gray, G., Sarafian, B., Linn, E., Bonomi, A., et al. (1993). The functional assessment of cancer therapy scale: Development and validation of the general measure. Journal of Clinical Oncology, 11(3), 570–579.CrossRefPubMed
10.
go back to reference Lin, X.-J., Lin, I. M., & Fan, S.-Y. (2013). Methodological issues in measuring health-related quality of life. Tzu Chi Medical Journal, 25(1), 8–12.CrossRef Lin, X.-J., Lin, I. M., & Fan, S.-Y. (2013). Methodological issues in measuring health-related quality of life. Tzu Chi Medical Journal, 25(1), 8–12.CrossRef
11.
go back to reference Karimi, M., & Brazier, J. (2016). Health, health-related quality of life, and quality of life: What is the difference? Pharmacoeconomics, 34(7), 645–649.CrossRefPubMed Karimi, M., & Brazier, J. (2016). Health, health-related quality of life, and quality of life: What is the difference? Pharmacoeconomics, 34(7), 645–649.CrossRefPubMed
12.
go back to reference Luckett, T., King, M. T., Butow, P. N., Oguchi, M., Rankin, N., Price, M. A., et al. (2011). Choosing between the EORTC QLQ-C30 and FACT-G for measuring health-related quality of life in cancer clinical research: Issues, evidence and recommendations. Annals of Oncology, 22(10), 2179–2190.CrossRefPubMed Luckett, T., King, M. T., Butow, P. N., Oguchi, M., Rankin, N., Price, M. A., et al. (2011). Choosing between the EORTC QLQ-C30 and FACT-G for measuring health-related quality of life in cancer clinical research: Issues, evidence and recommendations. Annals of Oncology, 22(10), 2179–2190.CrossRefPubMed
13.
go back to reference Watanabe, M., & Eto, K. (2015). Trends in clinical use of targeted therapy for gastrointestinal cancers. Journal of Cancer Metastasis and Treatment, 1(3), 163–171.CrossRef Watanabe, M., & Eto, K. (2015). Trends in clinical use of targeted therapy for gastrointestinal cancers. Journal of Cancer Metastasis and Treatment, 1(3), 163–171.CrossRef
14.
go back to reference Polat, U., Arpaci, A., Demir, S., Erdal, S., & Yalcin, S. (2014). Evaluation of quality of life and anxiety and depression levels in patients receiving chemotherapy for colorectal cancer: Impact of patient education before treatment initiation. Journal of Gastrointestinal Oncology, 5(4), 270–275.PubMedPubMedCentral Polat, U., Arpaci, A., Demir, S., Erdal, S., & Yalcin, S. (2014). Evaluation of quality of life and anxiety and depression levels in patients receiving chemotherapy for colorectal cancer: Impact of patient education before treatment initiation. Journal of Gastrointestinal Oncology, 5(4), 270–275.PubMedPubMedCentral
15.
go back to reference Zhang, M., Peng, L., Liu, W., Wen, Y., Wu, X., Zheng, M., et al. (2015). Physical and psychological predictors of quality of life in Chinese colorectal cancer patients during chemotherapy. Cancer Nursing, 38(4), 312–321.CrossRefPubMed Zhang, M., Peng, L., Liu, W., Wen, Y., Wu, X., Zheng, M., et al. (2015). Physical and psychological predictors of quality of life in Chinese colorectal cancer patients during chemotherapy. Cancer Nursing, 38(4), 312–321.CrossRefPubMed
16.
go back to reference Heinemann, V., Quietzsch, D., Gieseler, F., Gonnermann, M., Schonekas, H., Rost, A., et al. (2006). Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. Journal of Clinical Oncology, 24(24), 3946–3952.CrossRefPubMed Heinemann, V., Quietzsch, D., Gieseler, F., Gonnermann, M., Schonekas, H., Rost, A., et al. (2006). Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. Journal of Clinical Oncology, 24(24), 3946–3952.CrossRefPubMed
17.
go back to reference Mayrbäurl, B., Giesinger, J. M., Burgstaller, S., Piringer, G., Holzner, B., & Thaler, J. (2015). Quality of life across chemotherapy lines in patients with advanced colorectal cancer: A prospective single-center observational study. Supportive Care in Cancer, 24(2), 667–674.CrossRefPubMed Mayrbäurl, B., Giesinger, J. M., Burgstaller, S., Piringer, G., Holzner, B., & Thaler, J. (2015). Quality of life across chemotherapy lines in patients with advanced colorectal cancer: A prospective single-center observational study. Supportive Care in Cancer, 24(2), 667–674.CrossRefPubMed
18.
go back to reference Tebbutt, N. C., Wilson, K., Gebski, V. J., Cummins, M. M., Zannino, D., van Hazel, G. A., et al. (2010). Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: Results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study. Journal of Clinical Oncology, 28(19), 3191–3198.CrossRefPubMed Tebbutt, N. C., Wilson, K., Gebski, V. J., Cummins, M. M., Zannino, D., van Hazel, G. A., et al. (2010). Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: Results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study. Journal of Clinical Oncology, 28(19), 3191–3198.CrossRefPubMed
19.
go back to reference Ohtsu, A., Shah, M. A., Van Cutsem, E., Rha, S. Y., Sawaki, A., Park, S. R., et al. (2011). Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: A randomized, double-blind, placebo-controlled phase III study. Journal of Clinical Oncology, 29(30), 3968–3976.CrossRefPubMed Ohtsu, A., Shah, M. A., Van Cutsem, E., Rha, S. Y., Sawaki, A., Park, S. R., et al. (2011). Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: A randomized, double-blind, placebo-controlled phase III study. Journal of Clinical Oncology, 29(30), 3968–3976.CrossRefPubMed
20.
go back to reference Peeters, M., Price, T. J., Cervantes, A., Sobrero, A. F., Ducreux, M., Hotko, Y., et al. (2014). Final results from a randomized phase 3 study of FOLFIRI {+/-} panitumumab for second-line treatment of metastatic colorectal cancer. Annals of Oncology, 25(1), 107–116.CrossRefPubMed Peeters, M., Price, T. J., Cervantes, A., Sobrero, A. F., Ducreux, M., Hotko, Y., et al. (2014). Final results from a randomized phase 3 study of FOLFIRI {+/-} panitumumab for second-line treatment of metastatic colorectal cancer. Annals of Oncology, 25(1), 107–116.CrossRefPubMed
21.
go back to reference Sobrero, A. F., Maurel, J., Fehrenbacher, L., Scheithauer, W., Abubakr, Y. A., Lutz, M. P., et al. (2008). EPIC: Phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. Journal of Clinical Oncology, 26(14), 2311–2319.CrossRefPubMed Sobrero, A. F., Maurel, J., Fehrenbacher, L., Scheithauer, W., Abubakr, Y. A., Lutz, M. P., et al. (2008). EPIC: Phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. Journal of Clinical Oncology, 26(14), 2311–2319.CrossRefPubMed
22.
go back to reference Satoh, T., Bang, Y. J., Gotovkin, E. A., Hamamoto, Y., Kang, Y. K., Moiseyenko, V. M., et al. (2014). Quality of life in the trastuzumab for gastric cancer trial. The Oncologist, 19(7), 712–719.CrossRefPubMedPubMedCentral Satoh, T., Bang, Y. J., Gotovkin, E. A., Hamamoto, Y., Kang, Y. K., Moiseyenko, V. M., et al. (2014). Quality of life in the trastuzumab for gastric cancer trial. The Oncologist, 19(7), 712–719.CrossRefPubMedPubMedCentral
23.
go back to reference Al-Batran, S. E., Van Cutsem, E., Oh, S. C., Bodoky, G., Shimada, Y., Hironaka, S., et al. (2016). Quality- of-life and performance status results from the phase III RAINBOW study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated gastric or gastroesophageal junction adenocarcinoma. Annals of Oncology, 27(4), 673–679.CrossRefPubMedPubMedCentral Al-Batran, S. E., Van Cutsem, E., Oh, S. C., Bodoky, G., Shimada, Y., Hironaka, S., et al. (2016). Quality- of-life and performance status results from the phase III RAINBOW study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated gastric or gastroesophageal junction adenocarcinoma. Annals of Oncology, 27(4), 673–679.CrossRefPubMedPubMedCentral
24.
go back to reference Manjelievskaia, J., Brown, D., McGlynn, K. A., Anderson, W., Shriver, C. D., & Zhu, K. (2017). Chemotherapy use and survival among young and middle-aged patients with colon cancer. JAMA Surgery, 152(5), 452–459.CrossRefPubMedPubMedCentral Manjelievskaia, J., Brown, D., McGlynn, K. A., Anderson, W., Shriver, C. D., & Zhu, K. (2017). Chemotherapy use and survival among young and middle-aged patients with colon cancer. JAMA Surgery, 152(5), 452–459.CrossRefPubMedPubMedCentral
25.
go back to reference Tachi, T., Teramachi, H., Tanaka, K., Asano, S., Osawa, T., Kawashima, A., et al. (2015). The impact of outpatient chemotherapy-related adverse events on the quality of life of breast cancer patients. PLoS ONE, 10(4), e0124169.CrossRefPubMedPubMedCentral Tachi, T., Teramachi, H., Tanaka, K., Asano, S., Osawa, T., Kawashima, A., et al. (2015). The impact of outpatient chemotherapy-related adverse events on the quality of life of breast cancer patients. PLoS ONE, 10(4), e0124169.CrossRefPubMedPubMedCentral
26.
go back to reference Al-Batran, S. E., & Ajani, J. A. (2010). Impact of chemotherapy on quality of life in patients with metastatic esophagogastric cancer. Cancer, 116(11), 2511–2518.PubMed Al-Batran, S. E., & Ajani, J. A. (2010). Impact of chemotherapy on quality of life in patients with metastatic esophagogastric cancer. Cancer, 116(11), 2511–2518.PubMed
27.
go back to reference Smith, D. P., King, M. T., Egger, S., Berry, M. P., Stricker, P. D., Cozzi, P., et al. (2009). Quality of life three years after diagnosis of localised prostate cancer: Population based cohort study. British Medical Journal, 339, b4817.CrossRefPubMedPubMedCentral Smith, D. P., King, M. T., Egger, S., Berry, M. P., Stricker, P. D., Cozzi, P., et al. (2009). Quality of life three years after diagnosis of localised prostate cancer: Population based cohort study. British Medical Journal, 339, b4817.CrossRefPubMedPubMedCentral
28.
go back to reference Dehkordi, A., Heydarnejad, M. S., & Fatehi, D. (2009). Quality of life in cancer patients undergoing chemotherapy. Oman Medical Journal, 24(3), 204–207.PubMedPubMedCentral Dehkordi, A., Heydarnejad, M. S., & Fatehi, D. (2009). Quality of life in cancer patients undergoing chemotherapy. Oman Medical Journal, 24(3), 204–207.PubMedPubMedCentral
29.
go back to reference Hsueh-Wen, C., Li-Yin, C., Sheng-Miauh, H., Chen-Jeng, T., & Chen-Jei, T. (2016). Changes in symptom patterns and health related quality of life of cancer patients before and after chemotherapy. Journal of Traditional Chinese Medicine, 36(3), 326–331.CrossRef Hsueh-Wen, C., Li-Yin, C., Sheng-Miauh, H., Chen-Jeng, T., & Chen-Jei, T. (2016). Changes in symptom patterns and health related quality of life of cancer patients before and after chemotherapy. Journal of Traditional Chinese Medicine, 36(3), 326–331.CrossRef
30.
go back to reference Hong, J. S., Tian, J., & Wu, L. H. (2014). The influence of chemotherapy-induced neurotoxicity on psychological distress and sleep disturbance in cancer patients. Current Oncology, 21(4), 174–180.CrossRefPubMedPubMedCentral Hong, J. S., Tian, J., & Wu, L. H. (2014). The influence of chemotherapy-induced neurotoxicity on psychological distress and sleep disturbance in cancer patients. Current Oncology, 21(4), 174–180.CrossRefPubMedPubMedCentral
31.
go back to reference Ai, Z.-P., Gao, X.-L., Li, J.-F., Zhou, J.-R., & Wu, Y.-F. (2017). Changing trends and influencing factors of the quality of life of chemotherapy patients with breast cancer. Chinese Nursing Research, 4(1), 18–23.CrossRef Ai, Z.-P., Gao, X.-L., Li, J.-F., Zhou, J.-R., & Wu, Y.-F. (2017). Changing trends and influencing factors of the quality of life of chemotherapy patients with breast cancer. Chinese Nursing Research, 4(1), 18–23.CrossRef
32.
go back to reference Wright, F., D’Eramo Melkus, G., Hammer, M., Schmidt, B. L., Knobf, M. T., Paul, S. M., et al. (2015). Trajectories of evening fatigue in oncology outpatients receiving chemotherapy. Journal of Pain and Symptom Management, 50(2), 163–175.CrossRefPubMedPubMedCentral Wright, F., D’Eramo Melkus, G., Hammer, M., Schmidt, B. L., Knobf, M. T., Paul, S. M., et al. (2015). Trajectories of evening fatigue in oncology outpatients receiving chemotherapy. Journal of Pain and Symptom Management, 50(2), 163–175.CrossRefPubMedPubMedCentral
33.
go back to reference Wright, F., D’Eramo Melkus, G., Hammer, M., Schmidt, B. L., Knobf, M. T., Paul, S. M., et al. (2015). Predictors and trajectories of morning fatigue are distinct from evening fatigue. Journal of Pain and Symptom Management, 50(2), 176–189.CrossRefPubMedPubMedCentral Wright, F., D’Eramo Melkus, G., Hammer, M., Schmidt, B. L., Knobf, M. T., Paul, S. M., et al. (2015). Predictors and trajectories of morning fatigue are distinct from evening fatigue. Journal of Pain and Symptom Management, 50(2), 176–189.CrossRefPubMedPubMedCentral
34.
go back to reference Karnofsky, D., Abelmann, W. H., Craver, L. F., & Burchenal, J. H. (1948). The use of the nitrogen mustards in the palliative treatment of carcinoma. Cancer, 1(4), 634–656.CrossRef Karnofsky, D., Abelmann, W. H., Craver, L. F., & Burchenal, J. H. (1948). The use of the nitrogen mustards in the palliative treatment of carcinoma. Cancer, 1(4), 634–656.CrossRef
35.
go back to reference Sangha, O., Stucki, G., Liang, M. H., Fossel, A. H., & Katz, J. N. (2003). The Self-Administered Comorbidity Questionnaire: A new method to assess comorbidity for clinical and health services research. Arthritis and Rheumatism, 49(2), 156–163.CrossRefPubMed Sangha, O., Stucki, G., Liang, M. H., Fossel, A. H., & Katz, J. N. (2003). The Self-Administered Comorbidity Questionnaire: A new method to assess comorbidity for clinical and health services research. Arthritis and Rheumatism, 49(2), 156–163.CrossRefPubMed
36.
go back to reference Padilla, G. V., Ferrell, B., Grant, M. M., & Rhiner, M. (1990). Defining the content domain of quality of life for cancer patients with pain. Cancer Nursing, 13(2), 108–115.CrossRefPubMed Padilla, G. V., Ferrell, B., Grant, M. M., & Rhiner, M. (1990). Defining the content domain of quality of life for cancer patients with pain. Cancer Nursing, 13(2), 108–115.CrossRefPubMed
37.
go back to reference Padilla, G. V., Presant, C., Grant, M. M., Metter, G., Lipsett, J., & Heide, F. (1983). Quality of life index for patients with cancer. Research in Nursing and Health, 6(3), 117–126.CrossRefPubMed Padilla, G. V., Presant, C., Grant, M. M., Metter, G., Lipsett, J., & Heide, F. (1983). Quality of life index for patients with cancer. Research in Nursing and Health, 6(3), 117–126.CrossRefPubMed
38.
go back to reference Ferrell, B. R., Dow, K. H., & Grant, M. (1995). Measurement of the quality of life in cancer survivors. Quality of Life Research, 4(6), 523–531.CrossRefPubMed Ferrell, B. R., Dow, K. H., & Grant, M. (1995). Measurement of the quality of life in cancer survivors. Quality of Life Research, 4(6), 523–531.CrossRefPubMed
39.
go back to reference Ferrell, B. R. (1995). The impact of pain on quality of life. A decade of research. Nursing Clinics of North America, 30(4), 609–624.PubMed Ferrell, B. R. (1995). The impact of pain on quality of life. A decade of research. Nursing Clinics of North America, 30(4), 609–624.PubMed
40.
go back to reference Ware, J. Jr., Kosinski, M., & Keller, S. D. (1996). A 12-Item Short-Form Health Survey: Construction of scales and preliminary tests of reliability and validity. Medical Care, 34(3), 220–233.CrossRefPubMed Ware, J. Jr., Kosinski, M., & Keller, S. D. (1996). A 12-Item Short-Form Health Survey: Construction of scales and preliminary tests of reliability and validity. Medical Care, 34(3), 220–233.CrossRefPubMed
41.
go back to reference Enders, C. K. (2006). A primer on the use of modern missing-data methods in psychosomatic medicine research. Psychosomatic Medicine, 68(3), 427–436.CrossRefPubMed Enders, C. K. (2006). A primer on the use of modern missing-data methods in psychosomatic medicine research. Psychosomatic Medicine, 68(3), 427–436.CrossRefPubMed
42.
go back to reference Enders, C. K. (2010). Applied missing data analysis. New York: Guilford Press. Enders, C. K. (2010). Applied missing data analysis. New York: Guilford Press.
43.
go back to reference Graham, J. W. (2009). Missing data analysis: Making it work in the real world. Annual Review of Psychology, 60, 549–576.CrossRefPubMed Graham, J. W. (2009). Missing data analysis: Making it work in the real world. Annual Review of Psychology, 60, 549–576.CrossRefPubMed
44.
go back to reference McKnight, P. E., McKnight, K. M., Sidani, S., & Figueredo, A. J. (2007). Missing data: A gentle introduction. New York: Guildford Press. McKnight, P. E., McKnight, K. M., Sidani, S., & Figueredo, A. J. (2007). Missing data: A gentle introduction. New York: Guildford Press.
45.
go back to reference Schafer, J. L. (1997). Analysis of incomplete multivariate data. Boca Raton: Chapman & Hall/CRC.CrossRef Schafer, J. L. (1997). Analysis of incomplete multivariate data. Boca Raton: Chapman & Hall/CRC.CrossRef
46.
go back to reference Zhu, W. M. (1997). Making bootstraps statistical inferences: A tutorial. Research Quarterly for Exercise and Sport, 68(1), 44–55.CrossRefPubMed Zhu, W. M. (1997). Making bootstraps statistical inferences: A tutorial. Research Quarterly for Exercise and Sport, 68(1), 44–55.CrossRefPubMed
47.
go back to reference Schafer, J. L., & Graham, J. W. (2002). Missing data: Our view of the state of the art. Psychological Methods, 7(2), 147–177.CrossRefPubMed Schafer, J. L., & Graham, J. W. (2002). Missing data: Our view of the state of the art. Psychological Methods, 7(2), 147–177.CrossRefPubMed
48.
go back to reference Muthén, B., & Shedden, K. (1999). Finite mixture modeling with mixture outcomes using the EM algorithm. Biometrics, 55(2), 463–469.CrossRefPubMed Muthén, B., & Shedden, K. (1999). Finite mixture modeling with mixture outcomes using the EM algorithm. Biometrics, 55(2), 463–469.CrossRefPubMed
49.
go back to reference Singer, J. D., & Willett, J. B. (2003). Applied longitudinal data analysis: Modeling change and event occurence (1st ed.). New York: Oxford University Press.CrossRef Singer, J. D., & Willett, J. B. (2003). Applied longitudinal data analysis: Modeling change and event occurence (1st ed.). New York: Oxford University Press.CrossRef
50.
go back to reference Hox, J. J. (2010). Multilevel analysis: Techniques and applications (2nd ed.). New York: Routledge Academic: Taylor & Francis Group.CrossRef Hox, J. J. (2010). Multilevel analysis: Techniques and applications (2nd ed.). New York: Routledge Academic: Taylor & Francis Group.CrossRef
51.
go back to reference Carpenter, J., & Bithell, J. (2000). Bootstrap confidence intervals: When, which, what? A practical guide for medical statisticians. Statistics in Medicine, 19(9), 1141–1164.CrossRefPubMed Carpenter, J., & Bithell, J. (2000). Bootstrap confidence intervals: When, which, what? A practical guide for medical statisticians. Statistics in Medicine, 19(9), 1141–1164.CrossRefPubMed
52.
go back to reference Effron, B. (2000). The bootstrap and modern statistics. Journal of the American Statistical Association, 95(452), 1293–1296.CrossRef Effron, B. (2000). The bootstrap and modern statistics. Journal of the American Statistical Association, 95(452), 1293–1296.CrossRef
53.
go back to reference LaFleur, B. J., & Greevy, R. A. (2009). Introduction to permutation and resampling-based hypothesis tests. Journal of Clinical Child and Adolescent Psychology, 38(2), 286–294.CrossRefPubMed LaFleur, B. J., & Greevy, R. A. (2009). Introduction to permutation and resampling-based hypothesis tests. Journal of Clinical Child and Adolescent Psychology, 38(2), 286–294.CrossRefPubMed
54.
go back to reference Wehrens, R., Putter, H., & Buydens, L. M. C. (2000). The bootstrap: A tutorial. Chemometrics and Intelligent Laboratory Systems, 51(1), 35–52.CrossRef Wehrens, R., Putter, H., & Buydens, L. M. C. (2000). The bootstrap: A tutorial. Chemometrics and Intelligent Laboratory Systems, 51(1), 35–52.CrossRef
55.
go back to reference Wood, M. (2005). Bootstrapped confidence intervals as an approach to statistical inference. Organizational Research Methods, 8(4), 454–470.CrossRef Wood, M. (2005). Bootstrapped confidence intervals as an approach to statistical inference. Organizational Research Methods, 8(4), 454–470.CrossRef
56.
go back to reference Osaba, D. (1999). Interpreting the meaningfulness of changes in health-related quality of life scores: Lessons from studies in adults. International Journal of Cancer, 83(S12), 132–137.CrossRef Osaba, D. (1999). Interpreting the meaningfulness of changes in health-related quality of life scores: Lessons from studies in adults. International Journal of Cancer, 83(S12), 132–137.CrossRef
57.
go back to reference Ediebah, D. E., Coens, C., Maringwa, J. T., Quinten, C., Zikos, E., Ringash, J., et al. (2013). Effect of completion-time windows in the analysis of health-related quality of life outcomes in cancer patients. Annals of Oncology, 24(1), 231–237.CrossRefPubMed Ediebah, D. E., Coens, C., Maringwa, J. T., Quinten, C., Zikos, E., Ringash, J., et al. (2013). Effect of completion-time windows in the analysis of health-related quality of life outcomes in cancer patients. Annals of Oncology, 24(1), 231–237.CrossRefPubMed
58.
go back to reference Giesinger, J. M., Wintner, L. M., Zabernigg, A., Gamper, E. M., Oberguggenberger, A. S., Sztankay, M. J., et al. (2014). Assessing quality of life on the day of chemotherapy administration underestimates patients’ true symptom burden. BMC Cancer, 14(758), 1–7. Giesinger, J. M., Wintner, L. M., Zabernigg, A., Gamper, E. M., Oberguggenberger, A. S., Sztankay, M. J., et al. (2014). Assessing quality of life on the day of chemotherapy administration underestimates patients’ true symptom burden. BMC Cancer, 14(758), 1–7.
59.
go back to reference Turgay, A. S., Khorshid, L., & Eser, I. (2008). Effect of the first chemotherapy course on the quality of life of cancer patients in Turkey. Cancer Nursing, 31(6), E19–E23.CrossRefPubMed Turgay, A. S., Khorshid, L., & Eser, I. (2008). Effect of the first chemotherapy course on the quality of life of cancer patients in Turkey. Cancer Nursing, 31(6), E19–E23.CrossRefPubMed
60.
go back to reference Sun, V., Borneman, T., Koczywas, M., Cristea, M., Piper, B. F., Uman, G., et al. (2012). Quality of life and barriers to symptom management in colon cancer. European Journal of Oncology Nursing, 16(3), 276–280.CrossRefPubMed Sun, V., Borneman, T., Koczywas, M., Cristea, M., Piper, B. F., Uman, G., et al. (2012). Quality of life and barriers to symptom management in colon cancer. European Journal of Oncology Nursing, 16(3), 276–280.CrossRefPubMed
61.
go back to reference Sarna, L., Brown, J. K., Cooley, M. E., Williams, R. D., Chernecky, C., Padilla, G., et al. (2005). Quality of life and meaning of illness of women with lung cancer. Oncology Nursing Forum, 32(1), E9–E19.CrossRefPubMed Sarna, L., Brown, J. K., Cooley, M. E., Williams, R. D., Chernecky, C., Padilla, G., et al. (2005). Quality of life and meaning of illness of women with lung cancer. Oncology Nursing Forum, 32(1), E9–E19.CrossRefPubMed
62.
go back to reference Liu, L., Fiorentino, L., Rissling, M., Natarajan, L., Parker, B. A., Dimsdale, J. E., et al. (2013). Decreased health-related quality of life in women with breast cancer is associated with poor sleep. Behavioral Sleep Medicine, 11(3), 189–206.CrossRefPubMed Liu, L., Fiorentino, L., Rissling, M., Natarajan, L., Parker, B. A., Dimsdale, J. E., et al. (2013). Decreased health-related quality of life in women with breast cancer is associated with poor sleep. Behavioral Sleep Medicine, 11(3), 189–206.CrossRefPubMed
63.
go back to reference Ganz, P. A., Petersen, L., Bower, J. E., & Crespi, C. M. (2016). Impact of adjuvant endocrine therapy on quality of life and symptoms: Observational data over 12 months from the mind-body study. Journal of Clinical Oncology, 34(8), 816–824.CrossRefPubMedPubMedCentral Ganz, P. A., Petersen, L., Bower, J. E., & Crespi, C. M. (2016). Impact of adjuvant endocrine therapy on quality of life and symptoms: Observational data over 12 months from the mind-body study. Journal of Clinical Oncology, 34(8), 816–824.CrossRefPubMedPubMedCentral
64.
go back to reference Lewis, C., Xun, P., & He, K. (2016). Effects of adjuvant chemotherapy on recurrence, survival, and quality of life in stage II colon cancer patients: A 24-month follow-up. Supportive Care in Cancer, 24(4), 1463–1471.CrossRefPubMed Lewis, C., Xun, P., & He, K. (2016). Effects of adjuvant chemotherapy on recurrence, survival, and quality of life in stage II colon cancer patients: A 24-month follow-up. Supportive Care in Cancer, 24(4), 1463–1471.CrossRefPubMed
65.
go back to reference Joshi, S. S., Ortiz, S., Witherspoon, J. N., Rademaker, A., West, D. P., Anderson, R., et al. (2010). Effects of epidermal growth factor receptor inhibitor-induced dermatologic toxicities on quality of life. Cancer, 116(16), 3916–3923.CrossRefPubMed Joshi, S. S., Ortiz, S., Witherspoon, J. N., Rademaker, A., West, D. P., Anderson, R., et al. (2010). Effects of epidermal growth factor receptor inhibitor-induced dermatologic toxicities on quality of life. Cancer, 116(16), 3916–3923.CrossRefPubMed
66.
go back to reference Jansen, L., Hoffmeister, M., Chang-Claude, J., Koch, M., Brenner, H., & Arndt, V. (2011). Age-specific administration of chemotherapy and long-term quality of life in stage II and III colorectal cancer patients: A population-based prospective cohort. The Oncologist, 16, 1741–1751.CrossRefPubMedPubMedCentral Jansen, L., Hoffmeister, M., Chang-Claude, J., Koch, M., Brenner, H., & Arndt, V. (2011). Age-specific administration of chemotherapy and long-term quality of life in stage II and III colorectal cancer patients: A population-based prospective cohort. The Oncologist, 16, 1741–1751.CrossRefPubMedPubMedCentral
67.
go back to reference Arndt, V., Merx, H., Stegmaier, C., Ziegler, H., & Brenner, H. (2004). Quality of life in patients with colorectal cancer 1 year after diagnosis compared with the general population: A population-based study. Journal of Clinical Oncology, 22(23), 4829–4836.CrossRefPubMed Arndt, V., Merx, H., Stegmaier, C., Ziegler, H., & Brenner, H. (2004). Quality of life in patients with colorectal cancer 1 year after diagnosis compared with the general population: A population-based study. Journal of Clinical Oncology, 22(23), 4829–4836.CrossRefPubMed
68.
go back to reference Schwartz, C. E., & Sprangers, M. A. G. (1999). Methodological approaches for assessing response shift in longitudinal health-related quality-of-life research. Social Science & Medicine, 48(11), 1531–1548.CrossRef Schwartz, C. E., & Sprangers, M. A. G. (1999). Methodological approaches for assessing response shift in longitudinal health-related quality-of-life research. Social Science & Medicine, 48(11), 1531–1548.CrossRef
69.
go back to reference Mazzotti, E., Antonini Cappellini, G. C., Buconovo, S., Morese, R., Scoppola, A., Sebastiani, C., et al. (2012). Treatment-related side effects and quality of life in cancer patients. Supportive Care in Cancer, 20(10), 2553–2557.CrossRefPubMed Mazzotti, E., Antonini Cappellini, G. C., Buconovo, S., Morese, R., Scoppola, A., Sebastiani, C., et al. (2012). Treatment-related side effects and quality of life in cancer patients. Supportive Care in Cancer, 20(10), 2553–2557.CrossRefPubMed
70.
go back to reference Marventano, S., Forjaz, M., Grosso, G., Mistretta, A., Giorgianni, G., Platania, A., et al. (2013). Health related quality of life in colorectal cancer patients: State of the art. BMC Surgery, 13 Suppl 2, S15.CrossRefPubMed Marventano, S., Forjaz, M., Grosso, G., Mistretta, A., Giorgianni, G., Platania, A., et al. (2013). Health related quality of life in colorectal cancer patients: State of the art. BMC Surgery, 13 Suppl 2, S15.CrossRefPubMed
71.
go back to reference Wang, S. Y., Hsu, S. H., Gross, C. P., Sanft, T., Davidoff, A. J., Ma, X., et al. (2016). Association between time since cancer diagnosis and health-related quality of life: A population-level analysis. Value in Health, 19(5), 631–638.CrossRefPubMedPubMedCentral Wang, S. Y., Hsu, S. H., Gross, C. P., Sanft, T., Davidoff, A. J., Ma, X., et al. (2016). Association between time since cancer diagnosis and health-related quality of life: A population-level analysis. Value in Health, 19(5), 631–638.CrossRefPubMedPubMedCentral
72.
go back to reference Marino, P., Roche, H., Biron, P., Janvier, M., Spaeth, D., Fabbro, M., et al. (2008). Deterioration of quality of life of high-risk breast cancer patients treated with high-dose chemotherapy: The PEGASE 01 Quality of Life Study. Value in Health, 11(4), 709–718.CrossRefPubMed Marino, P., Roche, H., Biron, P., Janvier, M., Spaeth, D., Fabbro, M., et al. (2008). Deterioration of quality of life of high-risk breast cancer patients treated with high-dose chemotherapy: The PEGASE 01 Quality of Life Study. Value in Health, 11(4), 709–718.CrossRefPubMed
73.
go back to reference Denlinger, C. S., & Barsevick, A. M. (2009). The challenges of colorectal cancer survivorship. Journal of the National Comprehensive Cancer Network, 7(8), 883–894.CrossRefPubMedPubMedCentral Denlinger, C. S., & Barsevick, A. M. (2009). The challenges of colorectal cancer survivorship. Journal of the National Comprehensive Cancer Network, 7(8), 883–894.CrossRefPubMedPubMedCentral
Metagegevens
Titel
Quality of life of patients with gastrointestinal cancers undergoing chemotherapy
Auteurs
Ilufredo Y. Tantoy
Bruce A. Cooper
Anand Dhruva
Janine Cataldo
Steven M. Paul
Yvette P. Conley
Marilyn Hammer
Kord M. Kober
Jon D. Levine
Christine Miaskowski
Publicatiedatum
21-04-2018
Uitgeverij
Springer International Publishing
Gepubliceerd in
Quality of Life Research / Uitgave 7/2018
Print ISSN: 0962-9343
Elektronisch ISSN: 1573-2649
DOI
https://doi.org/10.1007/s11136-018-1860-1

Andere artikelen Uitgave 7/2018

Quality of Life Research 7/2018 Naar de uitgave

Special Section: Test Construction (by invitation only)

Fit for purpose and modern validity theory in clinical outcomes assessment